What do systematic reviews say?

Intervention not reported

The review found no eligible studies for this question.

• Thermal stability and storage of human insulin 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting insulin analogues vs regular human insulin

Short‐acting insulin analogues showed no clear difference in all‐cause mortality (N) compared with regular human insulin (moderate certainty).

• Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
  Peto OR 1.66 [0.41, 6.64]
  6 studies · 2519 participants
  Moderate
• Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting insulin analogues vs regular human insulin

• Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 2509 participants
  Low
• Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus 2016 · Cochrane Headline outcomes only
  OR 0.89 [0.71, 1.12]
  7 studies · 2459 participants
  Very low

Short‐acting insulin analogues vs regular human insulin

• Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 2608 participants
  Low
• Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus 2016 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 2608 participants
  Low

Short‐acting insulin analogues vs regular human insulin

• Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2 participants
  Very low
• Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting insulin analogues vs regular human insulin

The review found no eligible studies for this question.

• Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting insulin analogues vs regular human insulin

• Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 2667 participants
  Very low

Short‐acting insulin analogues vs regular human insulin

The review found no eligible studies for this question.

• Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting insulin analogues vs regular human insulin

The review found no eligible studies for this question.

• Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting insulin analogues vs regular human insulin

The review found no eligible studies for this question.

• Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting insulin analogues vs regular human insulin

The review found no eligible studies for this question.

• Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: insulin detemir vs NPH insulin

• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 873 participants
  Very low

Summary of findings: insulin detemir vs NPH insulin

Insulin detemir showed no clear difference in all‐cause mortality compared with NPH insulin (low certainty).

• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  Peto OR 0.74 [0.2, 2.65]
  8 studies · 2328 participants
  Low

Summary of findings: insulin detemir vs NPH insulin

Insulin detemir showed no clear difference in AEs other than hypoglycaemia (1) SAE (2) Overall AE (3) AE leading… compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  RR 0.88 [0.64, 1.2]
  1 study · 8 participants
  Moderate

Summary of findings: insulin detemir vs NPH insulin

The review found no eligible studies for this question.

• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: insulin detemir vs NPH insulin

• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 2233 participants
  Low

Summary of findings: insulin detemir vs NPH insulin

It is very uncertain whether insulin detemir changes diabetes‐related complications (1) Fatal MI (2) Fatal stroke (3)… compared with NPH insulin (very low certainty).

• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  RR 1.5 [0.68, 3.32]
  1 study · 2 participants
  Very low

Summary of findings: insulin detemir vs NPH insulin

It is very uncertain whether insulin detemir changes hypoglycaemic episodes (1) Severe hypoglycaemia (2) Serious… compared with NPH insulin (very low certainty).

• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  RR 0.45 [0.17, 1.2]
  1 study · 5 participants
  Very low

Insulin glargine vs NPH insulin

It is very uncertain whether insulin glargine changes diabetes‐related complications (1) Fatal MI (2) Fatal stroke (3)… compared with NPH insulin (very low certainty).

• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  RR 1.03 [0.6, 1.77]
  1 study · 4 participants
  Very low

Insulin glargine vs NPH insulin

It is very uncertain whether insulin glargine changes hypoglycaemic episodes(1) Severe hypoglycaemia (2) Serious… compared with NPH insulin (very low certainty).

• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  RR 0.68 [0.46, 1.01]
  1 study · 14 participants
  Very low